ProPhase Labs, Inc. (PRPH) stock
Close on Oct 19, 2026Market cap $119.68KP/E –Yield –
ProPhase Labs, Inc. saw revenue fall 31.2% to $3.85M over the twelve months to Jun 30, 2026. Free cash flow was -$8.34M. At the latest close the market valued the company at $119.68K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $119.68K
- P/E ratio
- –
- Price to sales
- 0.03
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -6971.77%
Fundamentals
- Revenue
- $3.85M
- Net income
- -$22.46M
- EPS, diluted
- -$1.74
- Free cash flow
- -$8.34M
- Book value per share
- -$0.22
- Diluted shares
- 14M
Trading
- Previous close
- $0.01
- Open
- $0.01
- Day's range
- $0.01 – $0.01
- Volume
- 1,242,165
- Average volume (20 days)
- 473,300
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | PRPH | S&P 500 | Difference | PRPH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.3% | +0.6% | −30.9 pts | ||
| 3 months | -87.1% | +3.4% | −90.5 pts | ||
| Year to date | -98.1% | +13.3% | −111.4 pts | ||
| 1 year | -99.8% | +16.6% | −116.4 pts | ||
| 3 years | -100.0% | +86.4% | −186.4 pts | -94.3% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.8 pts | -82.4% | +12.7% |
| 10 years | -99.9% | +318.9% | −418.8 pts | -51.1% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ProPhase Labs filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of ShareholdersUpdate
- Results
- Update
- Update
- Update
About ProPhase Labs
Pharmaceutical Preparations
The company operates in biotechnology, personal genomics, and consumer health sectors. Through its genomic testing platforms, it provides direct-to-consumer whole genome sequencing, health and ancestry reporting, and interactive data analysis tools, while also serving academic research institutions. Its therapeutic and diagnostic pipelines focus on pre-cancer screening assays and licensed pharmaceutical compounds undergoing research for oncology and inflammatory conditions. Additionally, the business markets branded herbal supplements formulated to support vitality and wellness.
Company profile, executives and historyProPhase Labs stock: common questions
What is ProPhase Labs's stock price?
PRPH closed at $0.01 on Oct 19, 2026, down 6.16% on the day.
What is ProPhase Labs's market cap?
ProPhase Labs was worth $119.68K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is PRPH's P/E ratio?
ProPhase Labs lost money over fiscal 2025 (diluted EPS -$1.74), so it has no meaningful P/E ratio.
How much revenue does ProPhase Labs make?
ProPhase Labs reported revenue of $3.85M for the twelve months to Jun 30, 2026, down 31.2% from a year earlier.
Does ProPhase Labs pay a dividend?
No. ProPhase Labs has not paid a cash dividend over the last twelve months.
How has PRPH stock performed over the past year?
Including dividends, PRPH returned -99.8% over the past year, against +16.6% for the S&P 500.
Who are ProPhase Labs's competitors?
Companies most similar to ProPhase Labs by business, industry and size include PTCHF, IMNM, ANL, RANI, PTPI.
See a number that looks wrong?